About Sinovac Biotech (NASDAQ:SVA)
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$72.43 million
Price / Sales6.85
Cash Flow$0.05 per share
Price / Cash160.61
Book Value$2.28 per share
Price / Book3.82
Return on EquityN/A
Return on AssetsN/A
Sinovac Biotech (NASDAQ:SVA) Frequently Asked Questions
What is Sinovac Biotech's stock symbol?
Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."
How were Sinovac Biotech's earnings last quarter?
Sinovac Biotech Ltd. (NASDAQ:SVA) issued its quarterly earnings results on Tuesday, August, 23rd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter. The biopharmaceutical company earned $1.38 billion during the quarter, compared to analysts' expectations of $18.49 billion. During the same period in the previous year, the company posted $0.02 earnings per share. View Sinovac Biotech's Earnings History.
Who are some of Sinovac Biotech's key competitors?
Some companies that are related to Sinovac Biotech include Biohaven Pharmaceutical (BHVN), Alder Biopharmaceuticals (ALDR), Regenxbio (RGNX), Mirati Therapeutics (MRTX), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Collegium Pharmaceutical (COLL), Flexion Therapeutics (FLXN), Jounce Therapeutics (JNCE), Pharming Group (PHGUF), Vanda Pharmaceuticals (VNDA), Consort Medical (CSRMY), MiMedx Group (MDXG), CymaBay Therapeutics (CBAY), Karyopharm Therapeutics (KPTI), Dova Pharmaceuticals (DOVA), ProMetic Life Sciences (PFSCF) and Anika Therapeutics (ANIK).
Who are Sinovac Biotech's key executives?
Sinovac Biotech's management team includes the folowing people:
- Weidong Yin, Chairman of the Board, President, Chief Executive Officer, Secretary (Age 48)
- Nan Wang, Chief Financial Officer (Age 46)
- Ming Xia, Vice President - Sales and Marketing of Sinovac Beijing (Age 38)
- Simon J. Anderson, Independent Director (Age 53)
- Jue Lee, Independent Director (Age 47)
- Yuk Lam Lo, Independent Director (Age 68)
- Meng Mei, Independent Director (Age 58)
Has Sinovac Biotech been receiving favorable news coverage?
News headlines about SVA stock have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sinovac Biotech earned a news impact score of 0.13 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 44.36 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Sinovac Biotech's major shareholders?
Sinovac Biotech's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.71%), Neumann Advisory Hong Kong Ltd (0.71%), Deutsche Bank AG (0.43%), Eqis Capital Management Inc. (0.27%) and Spark Investment Management LLC (0.12%). Company insiders that own Sinovac Biotech stock include James Todd Parsons and Scott Langille. View Institutional Ownership Trends for Sinovac Biotech.
Which major investors are buying Sinovac Biotech stock?
SVA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Neumann Advisory Hong Kong Ltd, Spark Investment Management LLC, Deutsche Bank AG and Eqis Capital Management Inc.. View Insider Buying and Selling for Sinovac Biotech.
How do I buy shares of Sinovac Biotech?
Shares of SVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sinovac Biotech's stock price today?
One share of SVA stock can currently be purchased for approximately $8.70.
How big of a company is Sinovac Biotech?
Sinovac Biotech has a market capitalization of $493.22 million and generates $72.43 million in revenue each year. The biopharmaceutical company earns $-590,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Sinovac Biotech employs 724 workers across the globe.
How can I contact Sinovac Biotech?
Sinovac Biotech's mailing address is 39 SHANGDI XI ROAD HAIDIAN DISTRICT, BEIJING F4, 100085. The biopharmaceutical company can be reached via phone at 86-10-8289-0088 or via email at [email protected]
MarketBeat Community Rating for Sinovac Biotech (SVA)MarketBeat's community ratings are surveys of what our community members think about Sinovac Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sinovac Biotech (NASDAQ:SVA) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Sinovac Biotech (NASDAQ:SVA) Earnings History and Estimates Chart
Sinovac Biotech (NASDAQ SVA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/22/2017||Q4 2016||$0.08||$31.37 million||View||N/A|
|11/28/2016||Q316||$0.05||$0.06||$16.76 million||$28.74 million||View||N/A|
|8/23/2016||Q2||($0.15)||$18.49 billion||$1.38 billion||View||Listen|
|11/11/2015||Q315||($0.02)||($0.03)||$27.10 million||$16.80 million||View||Listen|
|8/12/2015||Q215||($0.01)||$0.04||$15.70 million||$18.50 million||View||Listen|
|5/15/2015||Q115||$0.02||($0.04)||$12.70 million||$9.27 million||View||N/A|
|4/20/2015||Q414||$0.01||$0.02||$14.10 million||$22.90 million||View||N/A|
|8/14/2014||Q214||$0.01||($0.04)||$17.20 million||$12.10 million||View||N/A|
|3/19/2014||Q4 13||($0.01)||$0.10||$18.75 million||$22.90 million||View||N/A|
|8/13/2013||Q2 2013||$0.02||$17.45 million||View||N/A|
|5/28/2013||Q1 2013||($0.04)||$10.05 million||View||N/A|
|11/15/2012||Q312||($0.03)||($0.06)||$12.35 million||$14.30 million||View||N/A|
Sinovac Biotech (NASDAQ:SVA) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Sinovac Biotech (NASDAQ:SVA)
No dividend announcements for this company have been tracked by MarketBeat.com
Sinovac Biotech (NASDAQ SVA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 12.62%
Sinovac Biotech (NASDAQ SVA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|4/17/2017||James Todd Parsons||Director||Sell||272||$0.25||$68.00|
|4/13/2017||James Todd Parsons||Director||Sell||166,500||$0.25||$41,625.00|
|4/11/2017||James Todd Parsons||Director||Sell||33,500||$0.25||$8,375.00|
Sinovac Biotech (NASDAQ SVA) News Headlines
Sinovac Biotech (NASDAQ:SVA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sinovac Biotech (NASDAQ:SVA) Income Statement, Balance Sheet and Cash Flow Statement
Sinovac Biotech (NASDAQ SVA) Stock Chart for Tuesday, March, 20, 2018